This article was originally published in The Tan Sheet
Consumer perception research will be conducted to determine rules that would best assure truthful and nonmisleading health claims on dietary supplements, FDA tells Rep. David McIntosh (R-Ind.), chairman of the House Subcommittee on National Economic Growth, Natural Resources & Regulatory Affairs in a May 16 letter. Reps from academia, consumer research and advocacy groups called for such research at a public meeting April 4 (1"The Tan Sheet" April 10, p. 5). Responding to a March 13 letter from McIntosh on various aspects of the Pearson implementation process, FDA says the court ruling affects only dietary supplements because "FDA does not have authority to authorize health claims for conventional foods when such a claim would require a disclaimer to render it truthful and not misleading"
You may also be interested in...
The need for clear, easily understandable disclaimers on dietary supplements making health claims that do not meet the significant scientific agreement standard was stressed to FDA by numerous speakers at the agency's April 4 public meeting on the Pearson v. Shalala decision.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning